scholarly article | Q13442814 |
P2093 | author name string | Sture Lindegren | |
Lars Gedda | |||
Lovisa Göstring | |||
P2860 | cites work | Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90 | Q28143497 |
The deaf and the dumb: the biology of ErbB-2 and ErbB-3 | Q28185247 | ||
ErbB2 degradation mediated by the co-chaperone protein CHIP | Q28208008 | ||
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 | ||
Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin | Q30839490 | ||
Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold | Q33330736 | ||
125I-labeled human epidermal growth factor. Binding, internalization, and degradation in human fibroblasts | Q36198091 | ||
Down regulation of epidermal growth factor receptors: direct demonstration of receptor degradation in human fibroblasts | Q36210313 | ||
Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors | Q36720680 | ||
Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study. | Q36999363 | ||
Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin | Q37081037 | ||
A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer | Q37338986 | ||
Engineered affinity proteins for tumour-targeting applications | Q37430356 | ||
Geldanamycin and its anti-cancer activities | Q37619906 | ||
Chemical and radiochemical considerations in radiolabeling with α-emitting radionuclides. | Q37971505 | ||
Association with membrane protrusions makes ErbB2 an internalization-resistant receptor | Q38345553 | ||
Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers. | Q39943343 | ||
A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells | Q39943622 | ||
An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models | Q40025393 | ||
Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. | Q40274520 | ||
Geldanamycin stimulates internalization of ErbB2 in a proteasome-dependent way. | Q40340333 | ||
Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. | Q40748731 | ||
ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. | Q40966152 | ||
The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. | Q41469562 | ||
Geldanamycin induces ErbB-2 degradation by proteolytic fragmentation | Q42800575 | ||
Direct procedure for the production of 211At-labeled antibodies with an epsilon-lysyl-3-(trimethylstannyl)benzamide immunoconjugate | Q46429197 | ||
Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. | Q54667220 | ||
Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. | Q54673289 | ||
Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects | Q73075684 | ||
Radiation doses to the cell nucleus in single cells and cells in micrometastases in targeted therapy with (131)I labeled ligands or antibodies | Q73516010 | ||
Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma | Q85074832 | ||
P433 | issue | 4 | |
P304 | page(s) | 2574-2580 | |
P577 | publication date | 2016-08-10 | |
P1433 | published in | Oncology Letters | Q20640514 |
P1476 | title | 17AAG-induced internalisation of HER2-specific Affibody molecules | |
P478 | volume | 12 |
Q93086999 | Mathematical modeling of drug-induced receptor internalization in the HER2-positive SKBR3 breast cancer cell-line | cites work | P2860 |